We thank Dr. Marchegiani for the attention she has given us Freedom Press. However, before drawing definitive conclusions that could lead you to convince yourself that this is the norm, we invite you to read the underlying considerations.
Pharmaceutical Representatives (SFIs) should not have to deal with sales in order not to create conflicts of interest, they must in fact depend on a scientific service and not on a sales or marketing management. This is stated by Legislative Decree 541/92, Legislative Decree 219/06, the guidelines of the Conference of Regions on scientific information, regional laws and regulations, European directives and sentences of the Cassation which condemn those companies that use ISF as sellers.
Once the laws have been made, there must then be the Authorities in charge of enforcing them. In the specific case they are the AIFA, the carabinieri of the NAS, the financial police. However, if no one observes them, space is given to illegality in the almost certainty of impunity for those who commit a crime or force them to commit a crime.
After all, what can we expect if we consider that we have had a health minister whose wife was (and is) the general manager of Farmindustria, the big names of Farmindustria themselves are received at Palazzo Chigi or go to dinner with Renzi at the Academy Museum in Florence, at the foot of Michelangelo's David, and the Aleottis who give, obviously with absolute disinterest, apartments for the poor to the Municipality of Florence, mayors Renzi first Nardella now.
Do you think that we had almost obtained a Professional Register to protect citizens/patients from the abuses that companies could have done by using the ISF in a distorted way. Then a mysterious lobby "convinced" the offender Sen. Tomassini, to scuttle the law that would have constituted the Register at the last vote.
From 2007 to today, 15,000 ISFs have been made redundant, but no crisis for the companies that have continued to collect good earnings. The ISFs were simply no longer used to "sell" drugs to general practitioners, because the companies decided to focus on biotechnologies or super-specialist drugs that require few fixed costs (ISFs) and guarantee enormous profits.
OR
We repeat, the comparison is and remains a crime and fortunately it is not the norm, it remains a marginal fact. The problem is the improper, purely commercial use that many companies make of the ISF.
We suggest to Mr. Morabito a film on what happens "above" the ISF, or on healthcare in general, such as the cash prizes that the Local Health Authorities give to doctors for not prescribing drugs (isn't this a kind of comparison?) or how generic drugs are marketed whose market is dominated by an oligopoly of 5 companies or the hotel cost of a hospital bed and so on. You are spoiled for choice.
Dear Dr. Marchegiani, the ISF are not corruptors nor do they want to become one, nor do they want anyone to force them to do so. Those who make films and write in newspapers should prevent this from happening, but they must not stop at the surface, they must know the terms of the problem, otherwise it will never be addressed. If there is or will be a comparator crime, it will only and always be the fault of the ISF, and everything will continue as before.
Redazione Fedaiisf – 11/06/2016
Related news: Minister of Health Sacconi and Signora: how I cook Italians for you
Meeting between the government and managers of some of the major pharmaceutical companies
Florence, dinner at the Academy for big names in pharmaceuticals. With Renzi
Lorenzin and Zingaretti at dinner with Federfarma: controversy breaks out
Florence. Social housing, Menarini renovates ten more
Aleotti: "Renzi visits Menarini in Berlin, Italian industry is successful abroad"
Renzi opens up to the big names in medicine
The Menarini group with Renzi delivers 3 social housing units
Florence: Inauguration of the Menarini Baby Kindergarten
If Big Pharma knocks on the government
13,400 jobs lost in seven years. The union between a rock and a hard place
Legislative Decree 24 April 2006, n. 219 (art. 119 and following)
Cassation. The scientific informant is not a commercial agent
Senate. Summary report no. 315 dated 09/02/2006. President Tomassini